Clinical trials: Recurrent Malignant Brain Neoplasm
Metastatic Malignant Neoplasm in the Brain, Recurrent Non-Small Cell Lung Carcinoma
PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II-IV Non-small Cell Lung Cancer
This phase II trial studies how well intensity modulated radiation therapy adjusted by positron emission tomography (PET) scanning together with combination chemotherapy works in treating patients with stage II-IV non-small cell…
- Conditions
- Metastatic Malignant Neoplasm in the Brain, Recurrent Non-Small Cell Lung Carcinoma, Stage IIA Non-Small Cell Lung Carcinoma, Stage IIB Non-Small Cell Lung Carcinoma
- Trial name
- PAINT (NCT02073968)
- Testing
- Carboplatin, Computed Tomography, Intensity-Modulated Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Albert Einstein College of Medicine
Glioblastoma, IDH-wildtype, Glioblastoma
The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
Resection of glioblastoma in or near functional brain tissue is challenging because of the proximity of important structures to the tumor site.
- Conditions
- Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme of Brain, Astrocytoma, Malignant
- Trial name
- RECMAP (NCT06273176)
- Testing
- Awake mapping under local anesthesia, Asleep mapping under general anesthesia, Resection under general anesthesia without mapping
- Where
- 8 sites in United States, Belgium and 3 more
- Volunteers
- 225 people
- Sponsor
- Erasmus Medical Center
Giant Cell Glioblastoma, Glioblastoma
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
This partially randomized phase II trial with a safety run-in component studies the side effects and how well bevacizumab given with or without trebananib works in treating patients with brain tumors that have come back…
- Conditions
- Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma, Oligodendroglioma
- Trial name
- NCT01609790
- Testing
- Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 244 sites in United States, Canada
- Volunteers
- 137 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma (Skin), Metastatic Cancer
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
RATIONALE: Drugs used in chemotherapy, such as temozolomide, use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00068666
- Testing
- temozolomide, radiation therapy
- Where
- 45 sites in United States
- Volunteers
- 41 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Glioblastoma, Grade IV Astrocytoma
Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma
This is a single-arm, open-label, multicenter study in approximately 52 adults with primary (de novo) GB that has recurred or progressed (first or second recurrence, including this recurrence) after treatment(s) including surgery…
- Conditions
- Glioblastoma, Grade IV Astrocytoma, Glioblastoma Multiforme, Grade IV Glioma
- Trial name
- NCT02858895
- Testing
- MDNA55
- Where
- 7 sites in United States
- Volunteers
- 47 people
- Sponsor
- Medicenna Therapeutics, Inc.
Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary
Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary, Leukemia, Lymphoma
- Trial name
- NCT00112619
- Testing
- topotecan hydrochloride
- Where
- 11 sites in United States
- Volunteers
- 19 people
- Sponsor
- Pediatric Brain Tumor Consortium
Solid Tumor, Adult Central Nervous System Germ Cell Tumor
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
RATIONALE: Giving high-dose chemotherapy before an autologous stem cell transplant stops the growth of tumor cells by stopping them from dividing or killing them.
- Conditions
- Solid Tumor, Adult Central Nervous System Germ Cell Tumor, Adult Rhabdomyosarcoma, Childhood Central Nervous System Germ Cell Tumor
- Trial name
- NCT00638898
- Testing
- busulfan, melphalan, topotecan hydrochloride
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- City of Hope Medical Center
Glioblastoma
Ph I SU011248 + Irinotecan in Treatment of Pts w MG
Primary Objectives To determine maxi tolerated dose \& dose limiting toxicity of SU011248 + Irinotecan in recurrent MG pts not on EIAEDs To characterize safety \& tolerability of SU011248 + Irinotecan among pts w recurrent MG…
- Trial name
- NCT00611728
- Testing
- SU011248 & Irinotecan
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Duke University
Glioma, Glioblastoma
Sitagliptin in Recurrent/Progressive Grade 4 Glioma
Sitagliptin, when combined with standard-of-care drug bevacizumab, is being tested to 1) find out if it is effective at treating gliomas that have returned or progressed after treatment, and 2) find out what the highest dose of…
- Conditions
- Glioma, Glioblastoma, Recurrent Glioma, Recurrent Glioblastoma
- Trial name
- NCT07541781
- Testing
- Sitagliptin, Bevacizumab
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Kailin Yang, MD, PhD
Brain Stem Neoplasm, Pineal Region Neoplasm
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
This phase I trial studies the side effects and best dose of entinostat in treating pediatric patients with solid tumors that have come back or have not responded to treatment.
- Conditions
- Brain Stem Neoplasm, Pineal Region Neoplasm, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm
- Trial name
- NCT02780804
- Testing
- Entinostat, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 21 sites in United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma, Brain Tumor
LITT Followed by Hypofractionated RT for Recurrent Gliomas
The purpose of this study is to evaluate the treatment regimen of using Laser Interstitial Thermal Therapy (LITT) and Hypo-fractionated Radiation Therapy to treat patients with recurrent gliomas.
- Conditions
- Glioblastoma, Brain Tumor, Glioma, Neoplasms
- Trial name
- GCCC 19140 (NCT04181684)
- Testing
- Procedure: LITT, Hypo-Fractionated Radiation Therapy
- Where
- 4 sites in United States
- Volunteers
- 39 people
- Sponsor
- University of Maryland, Baltimore
Glioblastoma, Anaplastic Astrocytoma
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
Primary brain tumors are typically treated by surgery, radiation therapy and chemotherapy, either individually or in combination.
- Conditions
- Glioblastoma, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Glioma
- Trial name
- NCT02800486
- Testing
- Intra-arterial Cetuximab, Intra-arterial Mannitol, Hypofractionated re-irradiation
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Northwell Health
Brain and Central Nervous System Tumors
Gene Therapy in Treating Patients With Recurrent or Progressive Brain Tumors
RATIONALE: Inserting the gene for p53 into a person's brain cells may improve the body's ability to fight cancer. PURPOSE: Phase I trial to study the effectiveness of p53 gene therapy with SCH-58500 in treating patients who have…
- Trial name
- NCT00004080
- Testing
- recombinant adenovirus-p53 SCH-58500, conventional surgery
- Sponsor
- National Cancer Institute (NCI)
Adult Anaplastic Oligodendroglioma, Adult Mixed Glioma
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
This phase I/II trial is studying the side effects and best dose of imatinib mesylate and to see how well it works in treating patients with a recurrent brain tumor that has not responded to previous surgery and radiation…
- Conditions
- Adult Anaplastic Oligodendroglioma, Adult Mixed Glioma, Adult Oligodendroglioma, Recurrent Adult Brain Neoplasm
- Trial name
- NCT00049127
- Testing
- Imatinib Mesylate, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 229 sites in United States
- Volunteers
- 64 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Brain Cancer
Phase I/II Cabazitaxel for Recurrent Malignant Glioma
The goal of Part 1 of this clinical research study is to find the highest tolerable dose of cabazitaxel that can be given to patients with glioblastoma.
- Trial name
- NCT01740570
- Testing
- Cabazitaxel
- Sponsor
- M.D. Anderson Cancer Center
Glioblastoma, Gliosarcoma
Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)
Primary objective: To estimate 6-month progression free survival probability of pts w recurrent malignant gliomas treated w erlotinib + bevacizumab.
- Trial name
- NCT00671970
- Testing
- Bevacizumab and Erlotinib
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Duke University
Recurrent Glioblastoma Multiforme, Progressive Glioblastoma Multiforme
Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma
To determine the safety and tolerability of the maximum dose for laboratory engineered Herpes Simplex Virus-1 in patients who would not be eligible for surgical resection of recurrent glioma To determine the safety and…
- Conditions
- Recurrent Glioblastoma Multiforme, Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma or Gliosarcoma
- Trial name
- M032-HSV-1 (NCT02062827)
- Testing
- M032 (NSC 733972)
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Alabama at Birmingham
Brain Tumor, Cancer
000860: A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
Protocol # 000860 Background: Diffuse gliomas are tumors that affect the brain and spinal cord. Gliomas that develop in people with certain gene mutations (IDH1 or IDH2) are especially aggressive. Better treatments are needed.
- Trial name
- NCT05588141
- Testing
- Zotiraciclib
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- National Cancer Institute (NCI)
Brain Cancer, Recurrent Malignant Gliomas
Bevacizumab in the Radiation Treatment of Recurrent Malignant Glioma
This is a pilot study. The goal of this study is to test whether Bevacizumab is safe enough in patients with brain tumors so that a larger study can be conducted.
- Conditions
- Brain Cancer, Recurrent Malignant Gliomas, Primary Brain Tumor
- Trial name
- NCT00595322
- Testing
- bevacizumab and radiation (IMRT)
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Recurrent Glioblastoma Multiforme, Primary Glioblastoma Multiforme
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
This study will test an investigational drug called AZD1390 in combination with radiation therapy for the treatment of brain tumors. This is the first time AZD1390 is being given to patients.
- Conditions
- Recurrent Glioblastoma Multiforme, Primary Glioblastoma Multiforme, Brain Neoplasms, Malignant, Leptomeningeal Disease (LMD)
- Trial name
- NCT03423628
- Testing
- Radiation Therapy, AZD1390
- Where
- 11 sites in United States, Japan and 1 more
- Volunteers
- 159 people
- Sponsor
- AstraZeneca